Insider Selling: Charles River Laboratories International, Inc. (NYSE:CRL) EVP Sells $569,522.10 in Stock

Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) EVP Shannon M. Parisotto sold 2,279 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total value of $569,522.10. Following the sale, the executive vice president now directly owns 2,499 shares of the company’s stock, valued at $624,500.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Charles River Laboratories International Trading Up 1.9 %

Shares of CRL opened at $242.15 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $181.36 and a 52-week high of $396.14. The business’s fifty day moving average is $209.93 and its 200-day moving average is $219.23. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.14 and a current ratio of 1.40. The firm has a market cap of $12.32 billion, a price-to-earnings ratio of 28.52, a PEG ratio of 1.56 and a beta of 1.28.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently modified their holdings of CRL. Ronald Blue Trust Inc. bought a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $25,000. Pinnacle Financial Partners Inc. bought a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $26,000. Trustcore Financial Services LLC acquired a new stake in shares of Charles River Laboratories International during the 1st quarter valued at $28,000. Trust Co. of Vermont acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $29,000. Finally, SRS Capital Advisors Inc. acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $35,000. Institutional investors own 95.20% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, November 3rd. William Blair reissued an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday, November 2nd. Evercore ISI dropped their price target on Charles River Laboratories International to $260.00 in a report on Tuesday, August 9th. Wells Fargo & Company lowered their price objective on Charles River Laboratories International from $325.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 16th. Finally, Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research note on Thursday, September 29th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $298.42.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Further Reading

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.